基于组分的中药功效导向配伍
Efficacy-oriented compatibility for component-based Chinese medicine.
作者信息
Zhang Jun-hua, Zhu Yan, Fan Xiao-hui, Zhang Bo-li
机构信息
Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China.
Pharmaceutical Informatics Institute, Zhejiang University, Hangzhou 310058, China.
出版信息
Acta Pharmacol Sin. 2015 Jun;36(6):654-8. doi: 10.1038/aps.2015.8. Epub 2015 Apr 13.
Abstract
Single-target drugs have not achieved satisfactory therapeutic effects for complex diseases involving multiple factors. Instead, innovations in recent drug research and development have revealed the emergence of compound drugs, such as cocktail therapies and "polypills", as the frontier in new drug development. A traditional Chinese medicine (TCM) prescription that is usually composed of several medicinal herbs can serve a typical representative of compound medicines. Although the traditional compatibility theory of TCM cannot be well expressed using modern scientific language nowadays, the fundamental purpose of TCM compatibility can be understood as promoting efficacy and reducing toxicity. This paper introduces the theory and methods of efficacy-oriented compatibility for developing component-based Chinese medicines.
摘要
对于涉及多种因素的复杂疾病，单靶点药物尚未取得令人满意的治疗效果。相反，近年来药物研发的创新表明，复方药物如鸡尾酒疗法和“多效药丸”的出现，成为新药研发的前沿。通常由几种草药组成的中药方剂就是复方药物的典型代表。尽管如今中医传统配伍理论难以用现代科学语言充分表述，但中医配伍的根本目的可理解为增效减毒。本文介绍了基于组效关系研发中药组分药物的理论与方法。
相似文献
1
Efficacy-oriented compatibility for component-based Chinese medicine.基于组分的中药功效导向配伍
Acta Pharmacol Sin. 2015 Jun;36(6):654-8. doi: 10.1038/aps.2015.8. Epub 2015 Apr 13.
2
Fangjiomics: revealing adaptive omics pharmacological mechanisms of the myriad combination therapies to achieve personalized medicine.方剂组学：揭示多种联合疗法的适应性组学药理机制以实现个性化医疗。
Acta Pharmacol Sin. 2015 Jun;36(6):651-3. doi: 10.1038/aps.2015.33.
3
Diverse array-designed modes of combination therapies in Fangjiomics.方剂组学中多种基于阵列设计的联合治疗模式。
Acta Pharmacol Sin. 2015 Jun;36(6):680-8. doi: 10.1038/aps.2014.125. Epub 2015 Apr 13.
4
HERB: a high-throughput experiment- and reference-guided database of traditional Chinese medicine.中草药：一个基于高通量实验和参考指导的中草药数据库。
Nucleic Acids Res. 2021 Jan 8;49(D1):D1197-D1206. doi: 10.1093/nar/gkaa1063.
5
[Development and application of component-based Chinese medicine theory].[基于组件的中医理论的发展与应用]
Zhongguo Zhong Yao Za Zhi. 2017 Nov;42(21):4054-4058. doi: 10.19540/j.cnki.cjcmm.2017.0161.
6
[Study of means of formulating prescription based on combination disease with syndrome].基于病证结合的方剂配伍规律研究
Zhongguo Zhong Yao Za Zhi. 2009 Jan;34(1):2-5.
7
Herb pairs containing Angelicae Sinensis Radix (Danggui): A review of bio-active constituents and compatibility effects.含当归的药对：生物活性成分与配伍效应综述
J Ethnopharmacol. 2016 Apr 2;181:158-71. doi: 10.1016/j.jep.2016.01.033. Epub 2016 Jan 22.
8
Modern bioinformatics meets traditional Chinese medicine.现代生物信息学与传统中医学的交汇
Brief Bioinform. 2014 Nov;15(6):984-1003. doi: 10.1093/bib/bbt063. Epub 2013 Sep 24.
9
[Perspective and application of metabonomics in modern study of traditional Chinese medicine].代谢组学在现代中医药研究中的应用与展望
Zhongguo Zhong Yao Za Zhi. 2014 Aug;39(16):3010-7.
10
[Study on combination components and effectiveness of Chinese traditional herbal formulas].[中药复方配伍成分与药效的研究]
Zhongguo Zhong Yao Za Zhi. 2006 Jan;31(1):5-9.
引用本文的文献
1
Drug repurposing in traditional Chinese medicine: from empirical wisdom to modern therapeutic strategies.中药中的药物重新利用：从经验智慧到现代治疗策略。
Front Pharmacol. 2025 Jul 31;16:1631727. doi: 10.3389/fphar.2025.1631727. eCollection 2025.
2
Inhibition Effects of Patchouli Alcohol, Carvacrol, p-Cymene, Eucalyptol and Their Formulations Against Influenza Virus Pneumonia Through TLR4/NF-κB/NLRP3 Signaling Pathway.广藿香醇、香芹酚、对伞花烃、桉叶油素及其制剂通过TLR4/NF-κB/NLRP3信号通路对流感病毒肺炎的抑制作用
Chem Biol Drug Des. 2025 Aug;106(2):e70150. doi: 10.1111/cbdd.70150.
3
An active ingredient from the combination of Corydalis Rhizoma and Paeoniae Radix Alba relieves chronic compression injury-induced pain in rats by ameliorating AR/Mboat2-mediated ferroptosis in spinal cord neurons.延胡索和白芍组合中的一种活性成分通过改善脊髓神经元中AR/Mboat2介导的铁死亡来缓解大鼠慢性压迫性损伤所致疼痛。
Front Pharmacol. 2025 Mar 25;16:1558916. doi: 10.3389/fphar.2025.1558916. eCollection 2025.
4
A Comprehensive Review of Coptidis Rhizoma and Magnoliae Officinalis Cortex Drug Pair and Their Chemical Composition, Pharmacological Effects and Pharmacokinetics Analysis.黄连-厚朴药对的研究进展：化学成分、药理作用及药代动力学分析。
Drug Des Devel Ther. 2024 Oct 2;18:4413-4426. doi: 10.2147/DDDT.S477381. eCollection 2024.
5
Current Treatment Methods for Charcot-Marie-Tooth Diseases.Charcot-Marie-Tooth 病的治疗方法现状。
Biomolecules. 2024 Sep 9;14(9):1138. doi: 10.3390/biom14091138.
6
Danshen-Shanzha formula for the treatment of atherosclerosis: ethnopharmacological relevance, preparation methods, chemical constituents, pharmacokinetic properties, and pharmacological effects.丹参山楂方治疗动脉粥样硬化：民族药理学相关性、制备方法、化学成分、药代动力学特性及药理作用
Front Pharmacol. 2024 Jun 7;15:1380977. doi: 10.3389/fphar.2024.1380977. eCollection 2024.
7
Integration of transcriptomics and metabolomics reveals toxicological mechanisms of ZhuRiHeng drop pill in the 180-day repeated oral toxicity study.转录组学与代谢组学整合揭示了珠日恒滴丸在180天重复经口毒性研究中的毒理学机制。
Front Pharmacol. 2024 Mar 15;15:1333167. doi: 10.3389/fphar.2024.1333167. eCollection 2024.
8
Chinmedomics: a potent tool for the evaluation of traditional Chinese medicine efficacy and identification of its active components.中药组学：评估中药疗效及鉴定其活性成分的有力工具。
Chin Med. 2024 Mar 13;19(1):47. doi: 10.1186/s13020-024-00917-x.
9
Reveal the Patterns of Prescriptions for Recurrent Respiratory Tract Infections' Treatment Based on Multiple Illustrious Senior Traditional Chinese Medicine Practitioners.基于多位著名老中医揭示复发性呼吸道感染的治疗用药规律
Evid Based Complement Alternat Med. 2023 May 25;2023:7982927. doi: 10.1155/2023/7982927. eCollection 2023.
10
Efficacy analysis and research progress of complementary and alternative medicines in the adjuvant treatment of COVID-19.补充和替代医学在 COVID-19 辅助治疗中的疗效分析与研究进展。
J Biomed Sci. 2023 May 3;30(1):30. doi: 10.1186/s12929-023-00923-5.
本文引用的文献
1
Identifying roles of "Jun-Chen-Zuo-Shi" component herbs of QiShenYiQi formula in treating acute myocardial ischemia by network pharmacology.基于网络药理学探讨芪参益气方“君臣佐使”组分配伍治疗急性心肌缺血的作用机制。
Chin Med. 2014 Sep 16;9:24. doi: 10.1186/1749-8546-9-24. eCollection 2014.
2
A network pharmacology study of Chinese medicine QiShenYiQi to reveal its underlying multi-compound, multi-target, multi-pathway mode of action.一项关于中药芪参益气的网络药理学研究，以揭示其潜在的多成分、多靶点、多途径作用模式。
PLoS One. 2014 May 9;9(5):e95004. doi: 10.1371/journal.pone.0095004. eCollection 2014.
3
Qi-shen-yi-qi dripping pills for the secondary prevention of myocardial infarction: a randomised clinical trial.芪参益气滴丸用于心肌梗死后二级预防的随机临床试验。
Evid Based Complement Alternat Med. 2013;2013:738391. doi: 10.1155/2013/738391. Epub 2013 Jul 14.
4
Matching the power of high throughput screening to the chemical diversity of natural products.将高通量筛选的威力与天然产物的化学多样性相匹配。
Nat Prod Rep. 2013 Oct 11;30(10):1284-98. doi: 10.1039/c3np70052f. Epub 2013 Aug 8.
5
Shifting from the single to the multitarget paradigm in drug discovery.从单靶点到多靶点药物研发的转变。
Drug Discov Today. 2013 May;18(9-10):495-501. doi: 10.1016/j.drudis.2013.01.008. Epub 2013 Jan 20.
6
Target discovery from data mining approaches.从数据挖掘方法中发现目标。
Drug Discov Today. 2012 Feb;17 Suppl:S16-23. doi: 10.1016/j.drudis.2011.12.006. Epub 2011 Dec 15.
7
Developing a library of authenticated Traditional Chinese Medicinal (TCM) plants for systematic biological evaluation--rationale, methods and preliminary results from a Sino-American collaboration.建立经鉴定的中药材（TCM）植物库以进行系统的生物学评价——一项中美合作的基本原理、方法和初步结果。
Fitoterapia. 2011 Jan;82(1):17-33. doi: 10.1016/j.fitote.2010.11.017. Epub 2010 Nov 22.
8
High-throughput screening for bioactive components from traditional Chinese medicine.中药生物活性成分的高通量筛选
Comb Chem High Throughput Screen. 2010 Dec;13(10):837-48. doi: 10.2174/138620710793360257.
9
[Analysis of myocardial proteomic alteration after Qishenyiqi formula treatment in acute infarcted rat hearts].[芪参益气方对急性心肌梗死大鼠心脏治疗后心肌蛋白质组学变化的分析]
Zhongguo Zhong Yao Za Zhi. 2009 Apr;34(8):1018-21.
10
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.一种复方制剂（Polycap）对无心血管疾病中年个体危险因素的影响（TIPS）：一项II期双盲随机试验。
Lancet. 2009 Apr 18;373(9672):1341-51. doi: 10.1016/S0140-6736(09)60611-5. Epub 2009 Mar 30.
Zotero 插件